| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/17/2005 | US20050037090 Selected from Vitaxin, exemestane, anastrozole, letrozole, thiotepa, SU-5416, capecitabine, tamoxifen, raloxifene, fluoxymesterone, megestrol, toremifene, goserelin, ornithine decarboxylase inhibitors such as eflornithine, bisphosphonates and sulindac sulfone |
| 02/17/2005 | US20050037089 Administering a bone remodeling agent such as parathyroid hormone and a dietary supplement comprising calcium and phosphorus |
| 02/17/2005 | US20050037083 Activating a water insoluble drug in aqueous solution; freeze drying; intravenous injection; sonicating evaporation |
| 02/17/2005 | US20050037068 Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
| 02/17/2005 | US20050037066 Formulation and manufacturing process for Coenzyme Q10 soft gel capsules |
| 02/17/2005 | US20050037065 Fatty acids from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting; for pregnant or lactating women |
| 02/17/2005 | US20050037031 applying to the interior of the nasal cavity a cream which physically blocks communication between the smells and the olfactory nerves in the nasal cavity; dietetics |
| 02/17/2005 | US20050037025 Caffeine-free and tannin-free mixtures; anxiolytic and antiinflammatory agents, antidepressants, analgesics; tension, fatigue, headaches, psychological disorders |
| 02/17/2005 | US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 02/17/2005 | US20050037007 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring |
| 02/17/2005 | US20050036998 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/17/2005 | US20050036997 Molecular modeling of the binding sites for anisomycin, azithromycin, erythromycin, linezolid, tylosin, carbomycin A, spiramycin, virginiamycin, sparsomycin and blasticidin using the Haloarcular marismortui large ribosomal subunit; drug design and drug screening |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036960 contains a suspending agent (a clay like montmorillonite), a rinse-off resistant agent (maleic anyhydride terpolymers, polyvinylpyrillidone, and copolymers) and a skin protectant agent (oatmeal, soy, zinc oxide); free of oil and silicone |
| 02/17/2005 | US20050036952 Compositions and methods for the treatment of aches and pains |
| 02/17/2005 | US20050036949 A pharmaceutical dispenser; a liquid formulation comprising nitric oxide; respiratory system diseases; atomizing |
| 02/17/2005 | US20050036904 Chelation of calcium compound, demineralization; disinfecting; prevent kidney stones; atherosclerosis; administering antibiotics |
| 02/17/2005 | US20050035267 Furnace mount and method of installation |
| 02/17/2005 | US20050035266 Furnace Mount and Method of Installation |
| 02/17/2005 | DE10335027A1 Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis |
| 02/17/2005 | DE10333508A1 New recognition molecules for the prothrombin gene, useful for treatment, diagnosis and monitoring of thromboembolic disease, target a specific region in prothrombin mRNA |
| 02/17/2005 | DE10329925A1 Side-effect free inhalation anesthetic, especially useful in intensive care patients, comprises gaseous xenon, optionally in combination with organic hypnotic agents |
| 02/17/2005 | CA2535448A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions |
| 02/17/2005 | CA2535125A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2535026A1 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | CA2534693A1 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | CA2534528A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparationand use as modulators of apoptosis |
| 02/17/2005 | CA2534496A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2534480A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | CA2534415A1 Therapeutic delivery of carbon monoxide |
| 02/17/2005 | CA2534157A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | CA2534132A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | CA2534125A1 Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| 02/17/2005 | CA2534099A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | CA2534097A1 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/17/2005 | CA2533861A1 Combinations comprising staurosporines |
| 02/17/2005 | CA2533786A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | CA2531675A1 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/17/2005 | CA2529196A1 Benzodiazepine cgrp receptor antagonists |
| 02/17/2005 | CA2502148A1 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 02/17/2005 | CA2501889A1 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 02/16/2005 | EP1506787A1 Vascular endothelial cell growth factor antagonists |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506781A1 Vaginal care composition |
| 02/16/2005 | EP1506775A1 Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| 02/16/2005 | EP1506773A1 Sprayable skin protectant compositions |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506405A1 Method for identification of a ligand whereby receptor residence time is measured |
| 02/16/2005 | EP1506404A2 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system |
| 02/16/2005 | EP1506400A2 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor |
| 02/16/2005 | EP1506317A2 Marker molecules associated with lung tumors |
| 02/16/2005 | EP1506315A2 Method of identifying pancreatic ductal carcinoma (pdc) specific genes using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc |
| 02/16/2005 | EP1506306A2 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506237A1 Treatment of cancer by the use of anti fas antibody |
| 02/16/2005 | EP1506218A2 Reversible modification of membrane interaction |
| 02/16/2005 | EP1506215A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| 02/16/2005 | EP1506211A1 C-aryl glucoside sglt2 inhibitors and method |
| 02/16/2005 | EP1506193A1 Carbamate-substituted pyrazolopyridines |
| 02/16/2005 | EP1506178A2 Bicyclic modulators of androgen receptor function |
| 02/16/2005 | EP1506016A2 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
| 02/16/2005 | EP1506015A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 02/16/2005 | EP1506014A1 Process for the preparation and activation of substances and a means of producing same |
| 02/16/2005 | EP1506013A1 Chimeric allograft tolerance induction, monitoring and maintenance |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506009A2 Glucan-based vaccines |
| 02/16/2005 | EP1505994A1 Novel use of the extract of processed ginseng and saponin isolated therefrom |
| 02/16/2005 | EP1505990A2 Methods of treating hepatitis |
| 02/16/2005 | EP1505989A2 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| 02/16/2005 | EP1505988A1 Dual dispenser for aesthetically acceptable delivery of anhydrous skin treatment compositions |
| 02/16/2005 | EP1505986A1 COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER |
| 02/16/2005 | EP1505985A1 Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events |
| 02/16/2005 | EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 02/16/2005 | EP1505980A1 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission |
| 02/16/2005 | EP1505977A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 02/16/2005 | EP1505976A1 Synergistic combination of an opioid analgesic and a nsaid |
| 02/16/2005 | EP1505974A2 Use of compounds that are effective as selective opiate receptor modulators |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505972A2 A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| 02/16/2005 | EP1505971A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 02/16/2005 | EP1505967A1 Method for treating obesity |
| 02/16/2005 | EP1505965A1 Use of valsartan ot its metabolite to inhibit platelet aggregation |
| 02/16/2005 | EP1505963A1 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1505959A1 Use of edg receptor binding agents in cancer |
| 02/16/2005 | EP1505958A2 Coenzyme q products exhibiting high dissolution qualities |
| 02/16/2005 | EP1505873A2 Universal chimera bank |
| 02/16/2005 | EP1399501A4 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 02/16/2005 | EP1197223B1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582288A Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 |
| 02/16/2005 | CN1582284A Aminopyrimidines and pyridines |
| 02/16/2005 | CN1582283A Benzothiepine ileal bile acid transport inhibitors |
| 02/16/2005 | CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582178A Hematopoietic stem cell gene therapy |
| 02/16/2005 | CN1582168A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/16/2005 | CN1582167A Cytokine-inducing material and cytokine-inducing tool |
| 02/16/2005 | CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 02/16/2005 | CN1582160A Novel herbal chemical composition for treatment of cancer |